Biogen (BIIB) PT Lowered to $385 at Guggenheim
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $225.36 +2.87%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 10 | New: 48
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 10 | New: 48
Join SI Premium – FREE
Guggenheim lowered its price target on Biogen (NASDAQ: BIIB) to $385.00 (from $400.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Chord Energy Corp (CHRD) PT Lowered to $184 at UBS on Model Updates Following Non-Core Marcellus Sale
- Astra International Tbk PT (ASII:IJ) (PTAIY) PT Lowered to IDR6,450 at JPMorgan
- Ionis Pharmaceuticals (IONS) PT Lowered to $70 at JPMorgan Amid Negative Sentiment
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
GuggenheimSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
